Emotion Regulation Training Via Telehealth During the COVID-19 Pandemic
Launched by TEACHERS COLLEGE, COLUMBIA UNIVERSITY · Nov 2, 2020
Trial Information
Current as of August 28, 2025
Completed
Keywords
ClinConnect Summary
The present study is evaluating whether this ERT treatment program delivered via telehealth demonstrates efficacy in: 1) reducing symptoms of psychological distress (e.g., anxiety, depression, worry, rumination); 2) improving outcomes specific to the ERT mechanism-based model (e.g., attentional control, decentering, reappraisal); 3) improving quality of life and functioning, for adults aged 18-65 years old.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged 18-65 years during the time of participation
- • Endorses distress and worry/rumination exacerbated by the COVID-19 pandemic
- • Access to a mobile device (e.g., smartphone, personal computer, laptop, tablet) connected to the Internet
- Exclusion Criteria:
- • Active suicidal intent
- • Current substance dependence disorder (within the past year)
- • Current or past psychotic disorder, Bipolar-I disorder, or dementia
- • Primary DSM-5 diagnosis of borderline or narcissistic personality disorder
- • Currently receiving any other form of psychosocial treatment
About Teachers College, Columbia University
Teachers College, Columbia University, is a leading institution dedicated to advancing education, health, and human development through innovative research and rigorous academic programs. As a clinical trial sponsor, the College leverages its extensive expertise in educational psychology, health policy, and related fields to design and implement trials that aim to improve educational outcomes and mental health interventions. With a commitment to fostering evidence-based practices, Teachers College collaborates with diverse stakeholders to ensure that research findings translate into effective strategies that benefit learners and communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Trial Officials
Douglas S Mennin, Ph.D.
Principal Investigator
Teachers College, Columbia University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials